Imugene’s Azer-cel Earns FDA Fast Track for Two Blood Cancers After 100% ORR
Imugene's azer-cel has received dual FDA Fast Track Designation for two blood cancer indications, backed by Phase 1b data showing 100% ORR in CLL/SLL and 83% ORR in MZL, marking a significant regulatory milestone for the off-the-shelf CAR T programme.
Key Takeaways
- Imugene (ASX: IMU) has secured dual FDA Fast Track Designation for azer-cel across two blood cancer indications: relapsed or refractory CLL/SLL and Marginal Zone Lymphoma.
- Phase 1b clinical data underpinning the designation shows 100% overall response rate in CAR T-naive CLL/SLL patients and 83% ORR in MZL patients, including four complete responses.
- Fast Track Designation unlocks more frequent FDA engagement, rolling review eligibility, and potential pathways to Accelerated Approval and Priority Review.
- Azer-cel's allogeneic off-the-shelf design enables treatment readiness within days, compared to three to six weeks for autologous CAR T manufacturing, addressing a critical clinical need in rapidly progressing blood cancers.
![Maas Group Holdings Ltd Secures $855m Firmus Order and Lifts FY26 EBITDA Guidance [VIDEO]](https://media.stockwirex.com/factory_sign.jpg)
![Aland Equity Group Ltd Launches Capital Light Model With Elm Grove Heights Deal [VIDEO]](https://media.stockwirex.com/AEG-Elm-Grove-Heights.jpg)
![Imugene Ltd Notches Third Response in Azer Cel BTKi Cohort [VIDEO]](https://media.stockwirex.com/laboratory_with_signage.jpg)
![4DMEDICAL Ltd Eyes US$20M Veterans Lung Imaging Pilot in Bipartisan Bill [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F50ee8fd8-6e27-47e9-8f8b-bc44aecfe8a02Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer